Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Pentair

Both stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. An average and median increase of 15.13%.

2 Dividend Increases To Consider

Homebound families are spending more time and money on pets, Zoetis CEO Kristin Peck told CNBC's Jim Cramer on Wednesday.

Homebound families are spending more time and money on pets, Zoetis CEO says

IDEXX Laboratories

Nestle SA

PetMed Express

Rising pet ownership rates and a steadily increasing average household spending provide a powerful tailwind to this investment theme. Pet food, animal health, veterinary equipment, and specialized e-commerce are all fields prone to profit from the secular growth trend.

Growth In Pet Spending Is Off The Leash, Here Is How To Profit From It

Abbott Labs

Becton, Dickinson and Co.

AdvisorShares Focused Equity ETF

Eagle Bancorp

Globe Life Inc

HEICO

Hormel Foods

Miller Industries

RPM International

Thermo Fisher Scientific

This week's Alpha Trader podcast features hosts Aaron Task and Stephen Alpher speaking with LPL Financial's Ryan Detrick and Eddy Elfenbein, editor of the Crossing Wall Street blog and portfolio manager of the AdvisorShares Focused Equity ETF (CWS).

The 2021 Market Outlook And Some New Stock Picks - Ryan Detrick And Eddy Elfenbein Join Alpha Trader

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis will report Q4 and full year 2020 financial results on Tuesday, Feb 16, 2021.

Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2020 Financial Results

Church & Dwight

Chewy

Freshpet

Lemonade

PetIQ

Americans love their pets, and no pandemic, not even the novel coronavirus, will change that, bolstering these eight pet stocks. The post 8 Pet Stocks That Will Make You Purr appeared first on InvestorPlace.

8 Pet Stocks That Will Make You Purr

Alexandria Real Estate Equities

Hercules Capital

Merck

Vanguard Health Care ETF

These biotech stocks allow you to profit off the innovations that are giving us longer, healthier lives through the companies that make them. The post 5 Rational Biotech Stocks to Buy appeared first on InvestorPlace.

5 Rational Biotech Stocks to Buy

Cerner

Illumina

Intuitive Surgical

Pfizer

Teladoc

True, there are political risks in the industry. But there are also lots of growth opportunities for investors in healthcare stocks.

7 Healthcare Stocks to Buy With the Sector Under Scrutiny

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #JPM2021--Zoetis to present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021.

Zoetis to Participate in the 39th Annual J.P. Morgan Healthcare Conference

ZTS is the leader in the animal healthcare space, providing a multitude of products/services to customers. The company continues to have impressive earnings, even during the COVID pandemic and the management team is top tier.

Strong Fundamentals In The Animal Health Industry Will Drive Zoetis Shares To $200 And Beyond

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis declares Q1'21 dividend: Board approves 25% increase.

Zoetis Declares First Quarter 2021 Dividend; Board Approves 25% Payment Increase

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis appoints Antoinette (Tonie) Leatherberry to its Board of Directors.

Zoetis Appoints Tonie Leatherberry to Its Board of Directors

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock?

Zoetis (ZTS) Down 7.6% Since Last Earnings Report: Can It Rebound?

Covetrus Inc

FactSet Research Systems

Henry Schein

More households own pets than have children, and they'll pay to keep their furry friends happy. Here are 6 big pet stocks.

85 Million & Climbing: Why Pets = Profits for These 6 Companies

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #DiversityandInclusion--For the third year in a row, Zoetis has been named one of the "Top 75 Companies for Executive Women" by Working Mother Media.

Zoetis Named One of the “Top 75 Companies for Executive Women” by Working Mother Media

Bristol-Myers

Johnson & Johnson

Regeneron Pharmaceuticals

Sanofi

SPDR S&P Pharmaceuticals ETF

Pharmaceutical stocks help make the world go round. Without them, common ailments would plague our lives.

7 Pharmaceutical Stocks to Buy for 2021 and Beyond 

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #ESG--Zoetis is the first animal health company to issue Environmental, Social and Governance (ESG) Review based on leading sustainability frameworks.

Zoetis is First Animal Health Company to Issue Environmental, Social and Governance (ESG) Review Based on Leading Sustainability Frameworks

Zoetis (ZTS) gets marketing authorization for Librela, for monthly alleviation of osteoarthritis pain in dogs.

Zoetis (ZTS) Librela Gets Marketing Authorization in Europe

ZAVENTEM, Belgium--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis has received European Commission Marketing Authorization for Librela (bedinvetmab) for alleviation of osteoarthritis (OA) pain in dogs

Zoetis Receives European Commission Marketing Authorization for Librela® (bedinvetmab)

Zoetis Inc.'s (ZTS) CEO Kristin Peck on Q3 2020 Results - Earnings Call Transcript

Zoetis (ZTS) beats earnings and sales estimates in the third quarter. The company raises 2020 guidance.

Zoetis' (ZTS) Q3 Earnings and Revenues Surpass Estimates

Zoetis (ZTS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zoetis (ZTS) in Focus: Stock Moves 6.9% Higher

Zoetis (ZTS) delivered earnings and revenue surprises of 23.60% and 10.90%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) Tops Q3 Earnings and Revenue Estimates

Zoetis earnings beat views and the animal health giant hiked its guidance. Zoetis stock was little changed after spiking to a record high Wednesday.

Zoetis Earnings, Sales Top Expectations; Animal Health Giant Hikes Guidance

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis reports third quarter 2020 financial results.

News for Zoetis Stock (ZTS)